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CIRCULATING SOLUBLE TUMOR NECROSIS FACTOR
RECEPTORS, INTERLEUKIN-2 RECEPTORS,
TUMOR NECROSIS FACTOR a, AND
INTERLEUKIN-6 LEVELS IN 
RHEUMATOID ARTHRITIS
Longitudinal Evaluation During Methotrexate and Azathioprine Therapy
P1LAR B A R R E R A , A G N E S  M. T h . B O E R B O O M S . E L L Y  M. JA N S S E N . R O B ER T  W. SA U E R W E 1N .
H. G A L L A T l, JA N  M U L D E R , T H E O  DE BOO . P1ERRE N . M. D E M A C K E R ,
L E V IN U S  B. A. VAN DE PUTTE, and JOS W. M. v a n  d e r  M E E R
Objective. To assess whether circulating concen­
trations of soluble tumor necrosis factor receptors 
(sTNFR; p55 and p75), soluble interleukin-2 receptors 
(sIL-2R), tumor necrosis factor a  (TNFa), and 
interleukin-6 (IL-6) reflect clinical response and whether 
changes are dependent on the drug used in rheumatoid 
arthritis (RA) patients taking methotrexate (MTX) or 
azathioprine (AZA).
Methods. These cytokines and soluble receptors
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were assessed in 20 control subjects and serially for up 
to 48 weeks in 61 RA patients, by bioassay (IL-6) and 
immunoassays (sTNFR, sIL-2R, TNFa, and IL-6).
Results. Concentrations of p55 and p75, sIL-2R, 
and TNFa (but not IL-6) were significantly higher in RA 
patients than in controls. Significant decreases in sIL-2R 
and p55 concentrations were associated with clinical 
improvement and were observed in patients treated with 
MTX, but not AZA. Both treatments induced decreases 
in IL -6 concentrations, but circulating AZA (or its 
metabolites) appears to interfere with the measurement 
of IL -6 bioactivity. TNFa and p75 levels did not show 
significant changes.
Conclusion. Measurement of circulating sIL-2R, 
p55, and IL -6 may be useful in the evaluation of RA 
disease activity and response to therapy. Interference by 
circulating levels of drugs must be ruled out when 
bioassays are used to evaluate cytokine levels.
Accumulating evidence indicates that a number 
of cytokines are crucial in the pathogenesis of rheu­
matoid synovitis and other autoimmune diseases. Cy­
tokines such as interleukin-1 (IL-1), tumor necrosis 
factor a (TNFa), and IL-6 have been detected in 
rheumatoid synovium (1-8) and elevated concentra­
tions have been found in synovial fluid (SF) and serum 
of rheumatoid arthritis (RA) patients (9,10). Soluble 
receptor forms of several cytokines have been de­
scribed. The soluble IL-2 receptor (sIL-2R) is a trun­
cated form of the IL-2 receptor a chain (11). Levels of 
sIL-2R are markedly elevated in autoimmune diseases
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and are considered to be an activation marker of the 
immune system (12). Two types of TNF cell receptors 
have been identified (p55 and p75); both can be shed 
from the cell surface, yielding soluble fragments 
(13,14). These soluble receptor forms (sTNFR) func­
tion as TNF antagonists in vitro, although they may 
also prolong TNF activity by protecting it against 
degradation (15).
In RA , concentrations of IL-6 (16-18), sIL-2R 
(19), and sTNFR (20) are higher in SF than in serum, 
suggesting that the inflamed joint is the main produc­
tion site of these mediators. However, specimens for 
measurement in the circulation are easily obtained and 
more suitable for longitudinal studies. The effects of 
different disease-modifying antirheumatic drugs 
(DM ARDs) on circulating cytokines and their soluble 
receptors may be helpful in understanding their mech­
anism of action. So far, these effects have been eval­
uated mostly in cross-sectional or open studies, but 
comparative studies with different D M A R D s  are 
sparse.
In a recent randomized double-blind trial con­
ducted in our center, methotrexate (MTX) proved to 
be superior to azathioprine (AZA) in the treatment of 
active R A  (21,22). In the present study, circulating 
concentrations of sTNFR, sIL-2R, T N Fa, and IL-6 
were serially measured in patients included in the trial 
conducted by Jeurissen et al (21). The aim was to 
assess whether these concentrations (a) reflected dif­
ferences in clinical response, (b) correlated with each 
other and with clinical and laboratory parameters of 
disease activity, and (c) were differentially influenced 
by the drugs used.
PATIENTS AND METHODS
Patients. The details of the study have been exten­
sively described (21,22). Briefly, 64 patients with active 
definite or classic RA entered a 48-week, prospective, ran­
domized, double-blind trial of MTX versus AZA.
Active RA was defined by the presence of at least 3 
of the following 4 criteria: >6 joints tender or painful on 
motion, >3 swollen joints, erythrocyte sedimentation rate 
(ESR) >28 mm/hour, and morning stiffness >45 minutes in 
duration. Patients were randomly assigned to receive either 
MTX (initial dosage 7.5 mg weekly) or AZA (initial dosage 
100 mg daily). Dosages of nonsteroidal antiinflammatory 
drugs (NSAIDs) and prednisone (<10 mg/day) were stable 
for at least 4 weeks before study entry. At study entry 8 
patients taking AZA and 2 taking MTX had been on a stable 
regimen of low-dose prednisone (<10 mg/day). During the 
study period, the mean corticosteroid dosage did not change 
in any patient, but the NSAID dosage was increased in 3
patients (2 taking AZA and 1 taking MTX). Control sera 
were obtained from 20 healthy laboratory personnel working 
in our center.
Cytokine assays. Sera had been collected for subse­
quent analysis, along with concomitantly obtained data from 
clinical and laboratory evaluations, as part of the trial 
conducted by Jeurissen et al (21).
Sera were kept frozen at -20°C until assay. Cytokine 
levels were measured before treatment and at various inter­
vals up to 48 weeks of treatment. To minimize interassay 
variations, all samples from each patient were measured in a 
single assay. Levels of sIL-2R were measured using a 
“ sandwich” enzyme-linked immunosorbent assay (ELISA) 
(Cell-free; T Cell Sciences, Cambridge, MA), according to 
the manufacturer’s instructions. Results are expressed in 
units/ml relative to a set of standards provided with the test 
kit. The sensitivity of this assay is 50-100 units/ml.
TNFa was assessed by radioimmunoassay (RIA), as 
previously described (23). This RIA measures total TNFa 
(both free and complexed to its receptors), as demonstrated 
by the lack of interference of the addition of up to 5 ng/ml 
recombinant sTNFR (p55 and p75) to sera containing known 
amounts of TNFa (Barrera P et al: unpublished observa­
tions). The sensitivity of this RIA is between 10 and 100 
pg/ml (average 70 pg/ml).
IL-6 was measured by bioassay and ELISA. The 
IL-6 bioassay was performed as previously described (24). 
Briefly, 5,000 B9 cells were seeded in Iscove’s modified 
Dulbecco’s medium containing 5% fetal calf serum, penicil­
lin (100 IU/ml), streptomycin (100 /ng/ml), and /3-mercapto- 
ethanol (5 x 10_SM) in 96-well, flat-bottom microtiter plates 
(Costar, Badhoevedorp, The Netherlands) in the presence of 
serum samples or recombinant IL-6 standard (kind gift of Dr. 
L. A. Aarden, CLB, Amsterdam, The Netherlands). Cell 
proliferation was measured by thymidine incorporation after 
64 hours (7.4 kBq 3H-thymidine/well). Samples were heat 
inactivated for 30 minutes at 56°C, and tested in 2-fold 
dilutions. Half-maximal thymidine incorporation was de­
fined as 1 unit/ml IL-6. The sensitivity of this assay is 0.3 
units/ml.
The IL-6 ELISA (materials were a gift from Dr. J. 
Wijdenes, Innotherapy, Besançon, France) was performed 
as follows. Flat-bottom microtiter plates were coated for 24 
hours at 4°C with anti-IL-6 monoclonal antibody (MAb) BE8 
(7 ¡Ig/ml in phosphate buffered saline [PBS], 100 ¿d/well). 
The plates were washed, and serial dilutions of recombinant 
IL-6 and samples were added (100 ¿d/well) and incubated for
1 hour at 37°C. Plates were washed and incubated for 1 hour 
at room temperature with a second biotinylated anti-IL-6 
MAb, BE4 (2 ^g/ml in PBS with 0.25% bovine serum 
albumin [BSA], 100 /xl/well). After washing, horseradish 
peroxidase-streptavidin was added (4 /ig/ml in PBS with 
0.25% BSA 100 ¿¿.1/well), and plates were incubated for 45 
minutes at room temperature. Plates were washed and 
developed with a solution of 47% OPD in 14 mM citric acid 
and 36 mM trisodium citrate (pH 5.2, 100 ¿il/well; Merck). 
The reaction was stopped by addition of 2.5M H2S04 (50 
¿d/well). Plates were read at 492 nm in a Titertek Multiscan 
reader. The sensitivity of this ELISA is 20 units/ml.
Soluble TNF receptors (p55 and p75) were measured 
by enzyme-linked binding assay (Hoffmann-La Roche,
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Table 1. Course of treatment and clinical outcome in patients 
treated with azathioprine or methotrexate*
Time of study Azathioprine Methotrexate
No. of patients enrolled 33 31
Week 24
Continued therapy 20 30
No. (%) improved 12 (60) 23 (76)
Switched therapy 13 1
Reason Side effects Noncompliance
Week 48
Continued therapy 12 25
No. (%) improved 9 (75) 21 (84)
Switched therapy 8 5
Reason No effect Side effects/no effect
* Improvement determined according to the overall index (see 
Patients and Methods for details).
Basel, Switzerland). This assay measures total (both free 
and bound) receptor concentrations, since addition of up to
10 ng/ml recombinant TNFa to serum containing known 
amounts of sTNFR does not influence the assay. The sensi­
tivity of this assay is 100 pg/ml.
Definition of clinical improvement. The clinical out­
come was evaluated by means of an overall index. This 
index was based on the same parameters used to define 
active RA for study inclusion: 1) patient’s assessment of 
pain, using a visual analog scale (0 mm = no pain, 100 mm = 
very severe pain), 2) Ritchie articular index, 3) ESR, and 4) 
duration of morning stiffness. Improvement was defined as 
>30% reduction in at least 2 of these 4 values and no 
worsening of the other variables. Stable disease was defined 
as 0-29% reduction in the 4 variables. Worsening was 
defined as an increase in the 4 values compared with baseline 
(21,22). To simplify, we compared patients with improve­
ment versus those with lack of effect (stable disease or 
worsening).
Statistical analysis. Unless otherwise specified, data 
are expressed as the median and range. Since the variables 
studied were not normally distributed, distribution-free 
methods were applied. Comparisons of sTNFR, sIL-2R, 
TNFa, and IL-6 concentrations during therapy with pre­
treatment concentrations were made by Wilcoxon signed 
rank test for paired samples. To utilize all data gathered 
during the followup, comparison between both therapies 
(MTX versus AZA) and between patients with clinical
improvement versus those with lack of effect was analyzed 
by a distribution-free test for curve analysis (25). Compari­
son of therapy groups included only patients who completed 
24 weeks and 48 weeks of treatment with the originally 
assigned drug. The analysis according to clinical response 
included all patients randomized into the study, irrespective 
of therapy. Correlations were evaluated using Spearman's 
rank correlation coefficient for each data point during the 
followup.
RESULTS
Clinical results. The clinical and radiographic 
findings in this study have been published elsewhere 
(21,22). Com parison between treatment groups 
showed significantly more improvement in the M TX 
group, both in clinical and laboratory measurements of 
disease activity. Patients treated with M T X  showed a 
more rapid clinical improvement and less radiographic 
progression than did those treated with A ZA . Switch­
ing to another therapy due to adverse reactions or lack 
of effect of the initial D M A R D  was more often neces­
sary in the A ZA  group. Irrespective of the therapy, a 
total of 44 and 46 patients experienced clinical im ­
provement after 24 and 48 weeks, respectively. The 
course of treatment and the clinical outcome are 
summarized in Table 1.
Pretreatment cytokine concentrations. Data on 3 
patients (2 taking M TX and 1 taking A ZA ), 2 of whom 
showed clinical improvement, were excluded from 
analysis because no pretreatment sera were available. 
Baseline concentrations of sIL-2R (P <  0.0001), T N Fa  
(P <  0.02), and the soluble TN F receptors p55 (P = 
0.0001) and p75 (P <  0.04) were significantly higher in 
the RA  patients than in the control group. In contrast, 
IL-6 bioactivity in the patients did not differ signifi­
cantly from that in the controls (Table 2). T N F a  was 
undetectable in 8 patients (1 M TX; 7 AZA ) and in 10
Table 2. Concentrations of sTNFR (p55 and p75), TNFa, sIL-2R, and bioactive IL-6 in rheumatoid 
arthritis patients at baseline and in healthy controls*
Group (n)
sTNFR
p55
(pg/ml)
p75
(pg/ml)
TNFa
(pg/ml)
sIL-2R
units/ml
IL-6
units/ml
Patients (61)
Median 3,000t 2,970* 130+ 1,380t 11.6
Range 1,650-7,900t 0-15,700+ 0-3301 365-19,8001* 0.8-74.7
Controls (20)
Median 1,310 2,380 55 300 8.5
Range 0-1,970 1,360-3,480 0-260 0-730 7-13.5
* sTNFR = soluble tumor necrosis factor receptor; sIL-2R = soluble interleukin-2 receptor, 
t P < 0.0005 versus controls.
X P < 0.05 versus controls.
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Figure 1. Concentrations of p55 and p75 soluble tumor necrosis factor receptors in the serum of rheumatoid arthritis patients with clinical 
improvement (A) and with lack of response to therapy (B) after 24 weeks. Horizontal bars show the median. ** = significant change from 
baseline (P <  0.005); f  = concentration above the range of the y axis.
controls; p75 was undetectable in 13 patients (6 M TX;
7 AZA). Pretreatment cytokine concentrations were 
similar in both treatment groups and in patients who 
showed clinical improvement or a lack of effect at the 
end of the study.
Cytokine concentrations during follovvup. The 
differences between patients with and without clinical 
improvement were examined. Since analysis after 24 
and 48 weeks of treatment yielded similar results, only 
the data after 24 weeks are presented. At that time, 42 
patients showed clinical improvement and 19 showed a 
lack of response. Significant decreases in p55 concen­
trations (P <  0.005) were observed only in the patients 
with clinical improvement; in contrast, p75 concentra­
tions did not change significantly in either group 
(Figure 1). A steady decrease in sIL-2R concentrations 
(P <  0.05 from week 8 onward) occurred in the 
patients with clinical improvement, but (except for 
week 16) no significant change was observed in the 
patients with lack of response to therapy (Figure 2). 
Although T N Fa  concentrations did not decrease in 
either group over the followup period, lower levels 
were observed in the patients with clinical response 
compared with those with a lack of effect {P <  0.02)
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Figure 2. Concentrations of soluble interleukin-2 receptors (sIL2R) in the serum of rheumatoid arthritis patients with clinical improvement (A)
and with lack of response to therapy (B) after 24 weeks. Horizontal bars show the median. ** = P <  0.005 and *** = P <  0.0005 versus baseline.
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Figure 3. Concentrations of tumor necrosis factor (TNFa) in the serum of rheumatoid arthritis patients with clinical improvement (A) and with 
lack of response to therapy (B) after 24 weeks. Horizontal bars show the median. | = concentration above the range of the y axis.
(Figure 3). IL-6 bioactivity decreased after 4 weeks, 
both in patients who improved (P <  0.05) and even 
more markedly in those with a lack of effect (P < 
0.005); the differences between these 2 groups, how­
ever, were not significant (Figure 4).
When data were analyzed according to therapy, 
significant decreases in p55 (P = 0.01 after 24 weeks) 
and slL-2R (P <  0.005 from week 8 onward) concen­
trations were observed only in patients treated with 
M TX (Table 3). Furthermore, sIL-2R levels in the 
A ZA  group were significantly higher than those in the 
M TX group over the followup period (P = 0.02). 
Concentrations of bioactive IL-6 decreased in both 
treatment groups. However, in contrast to the results
obtained for sIL-2R and p55, this decrease was more 
marked and occurred earlier in patients treated with 
A ZA  (P <  0.0001 by week 4) than in those treated with 
M TX (P <  0.05 after 16 weeks of treatment) (Figure 5). 
Over the followup period, IL-6 bioactivity was signif­
icantly lower in the A Z A  group than in the M T X  group 
(P <  0.02). The concentrations of T N F a  and p75 did 
not show significant changes in any of the groups.
Measurement of IL -6 levels by ELISA. In contrast 
to the superiority of A Z A  over M T X  in decreasing 
IL-6 bioactivity, M T X  seemed slightly more effective 
at decreasing immunoreactive IL-6 concentrations: 
After 24 and 48 weeks, immunoreactive IL-6 levels 
decreased beyond the detection limit in 60% and 55%
* + ★ * * + + * ★
Figure 4. Concentrations of bioactive interleukin-6 (IL-6) in the serum of rheumatoid arthritis patients with clinical improvement (A) and with
lack of response to therapy (B) after 24 weeks. Horizontal bars show the median. * = P <  0.05, ** = P <  0.005, and *** = P <  0.0005 versus
baseline.
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Table 3. Concentrations of sTNFR (p55 and p75), TNFa, and sIL-2R in RA patients at baseline and percentage of change after 24 and 48 
weeks of treatment with MTX or AZA*
Baseline levels % change at week 24 % change at week 48
AZA MTX AZA MTX AZA MTX
(n = 32) (n = 29) (n = 19) (n = 28) (n = 12) (n = 24)
sTNFR (pg/ml)
p55
Median or %  change 3,075 2,875 -6.5 — 19.7+ -9.2 -7.2
Range or (25, 75 percentile) 2,250-4,150 2,250-3,575 (-22.2, 22.8) (-29.7, -6.4) (-21.7, 24.1) (-28.9, 21.8)
p75
Median or % change 3,175 2,400 -31.1 -4.2 -35 -18
Range or (25, 75 percentile) 2,375-5,525 1,675-4,450 (-72.8, 52.3) (-53.5, 24.2) (-53.6, -5.6) (-53.3, 20)
TNFa
Median or %  change 105 130 7.6 0 4.5 1.7
Range or (25, 75 percentile) 45-220 100-200 (-16.6, 17.6) (-23.3, 45.4) (-12.4, 26.7) (-14.3, 106.3)
sIL-2R 0'
Median or %  change 1,480 1,300 -22.6 -24 .lt -27.9 —28.2$
Range or (25, 75 percentile) 987^,700 890-4,250 (-42, 3.2) (-51.1, 6.5) (-37.7, 12.1) (-55, -5.6)
* All rheumatoid arthritis (RA) patients whose data are included had continued to take the assigned study drug. MTX = methotrexate; AZA 
= azathioprine. See Table 2 for other abbreviations, 
t P <  0.05 versus baseline.
X P <  0.0005 versus baseline.
of the patients treated with M T X  and in 47% and 50% 
of those treated with A ZA , respectively (Figure 6). 
Subsequent experiments showed that serum from pa­
tients treated with A Z A  (but not MTX) exerted an 
inhibitory effect on the IL-6 bioassay (Barrera P et al: 
unpublished observations).
Interrelationships between cytokines and soluble 
receptors and correlation with disease activity parame­
ters. In the entire group of 61 patients, a significant 
correlation between sIL-2R and p55 (r >  0.50, P < 
0.0005) was observed during followup. In contrast, the
correlation between sIL-2R and p75 was weaker and 
present only at baseline (r = 0.37, P <  0.005). Both 
sTNFR correlated significantly with each other (r >  
0.50, P <  0.0005). T N Fa  concentrations showed no 
significant correlations with either sTNFR or any of 
the parameters studied. The positive correlations be­
tween pretreatment IL-6 bioactivity and sIL-2R and 
sTNFR in the RA  patients tended to decrease during 
the followup (data not shown); however, this was not 
the case when only the patients treated with M TX 
were analyzed (correlation coefficients between IL-6
+ + ♦ + + + + ♦* + *
o
cs
o
so
à
40
0.4
A
•  *
« •
•  •
•••I 
•  •
•  •
8 16 
time (weeks)
•  •
24 48
Figure 5. Concentrations of bioactive interleukin-6 (IL-6) in the serum of rheumatoid arthritis patients treated with methotrexate (A) or with
azathioprine (B) for 24 weeks (n = 28 and n = 19) and 48 weeks (n = 23 and n = 11). Horizontal bars show the median. * = P <  0.05, ** =
P <  0.005, and *** = P <  0.0005 versus baseline.
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Figure 6. Concentrations of immunoactive interleukin-6 (IL-6) in the serum of rheumatoid arthritis patients treated with methotrexate (A) or 
with azathioprine (B) for 24 weeks (n = 28 and n = 19) and 48 weeks (n = 23 and n = 11). Horizontal bars show the median. Faint line near 
20 units/ml represents the detection limit of the enzyme-linked immunosorbent assay, f  = concentration above the range of the y axis.
and sIL-2R, p55, and p75, respectively, were 0.65, 
0.34, and 0.44).
The parameters measured in this study showed 
no significant correlation with clinical (disease dura­
tion, Ritchie articular index, number of tender joints, 
duration of morning stiffness, and disease activity 
score [26]) or with radiologic (erosion score and total 
score [21]) measurements. On the other hand, positive 
correlations were found with some laboratory para­
meters of disease activity, such as the C-reactive 
protein (CRP) level, the ESR , and the platelet count 
(Table 4).
DISCUSSION
In this study, circulating levels of sTNFR, 
sIL-2R, T N Fa, and IL-6 were serially measured in 
patients with active RA  randomized to receive treat­
ment with M T X  or A ZA . A number of interesting 
findings emerged from these investigations. First, we 
found that concentrations of both of the sTNFR (p55 
and p75), sIL-2R, and T N Fa  are significantly elevated 
in patients with RA  as compared with normal controls. 
Similar observations for sTNFR and sIL-2R have been 
reported by other investigators (19,20,27). With re­
spect to T N Fa , the results reported in the literature 
are conflicting (see below). Despite active RA  before 
treatment, elevated immunoactive and bioactive IL-6 
concentrations were observed only in some of the 
patients, resulting in mean IL-6 concentrations that 
were not significantly higher than in controls. The 
relatively low serum IL-6 concentrations in this and
other studies (16-18) and the thousandfold higher 
levels found in synovial fluid suggest a predominant 
intraarticular production or a rapid clearance of the 
circulating IL-6.
A second important finding in our study is that 
clinical improvement is accompanied by significant 
reductions in the concentrations of p55 and sIL-2R, 
the parameters which best correlated with laboratory 
indices of RA  activity such as CRP, ESR , and platelet 
counts. Decreases in sIL-2R concentrations, together 
with clinical improvement, have been observed in RA  
(28-30), and associations between sTNFR levels and 
disease severity were recently reported in a cross- 
sectional study (27). However, to our knowledge, this 
is the first report of a long-term study of concomitant 
measurements of circulating levels of T N F a  and 
sTNFR in RA . The following observations are proba-
Table 4. Spearman correlation coefficient among pretreatment 
concentrations of sTNFR (p55, p75), sIL-2R, bioactive IL-6, and 
laboratory parameters of disease activity*
ESR CRP Platelets
sTNFR
p55 0.38+ 0.63+ 0.36+
p75 0.19 0.40+ 0.26§
S1L-2R 0.38+ 0.50+ 0.40+
IL-6 0.28§ 0.41 + 0.29§
* ESR = erythrocyte sedimentation rate; CRP = C-reactive protein. 
See Table 2 for other abbreviations, 
t P <  0.005. 
t P <  0.0005.
§ P <  0.05.
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bly relevant: (a) The concentrations of each type of 
sTNFR individually exceeded by 20-30-fold those of 
T N Fa, the p75 sTNFR levels being higher than those 
of p55; (b) The T N F a  concentrations throughout the 
study period were higher in patients with lack of 
response to therapy than in those who improved; and 
(c) A  decrease in p55 sTNFR concentrations occurred 
in patients with clinical improvement, but no signifi­
cant changes in T N F a  or p75 concentrations were 
observed, irrespective of response to therapy or the 
D M A R D  used.
Elevated T N F a  levels and correlations with 
disease severity have been found in various infectious 
and noninfectious diseases (31-33). Similar observa­
tions in R A  (34—36) have not been confirmed in other 
studies which failed to detect circulating T N Fa  (27). 
Some of these discrepancies are probably due to the 
presence of sTNFR in biological fluids, which may 
interfere to a different extent in TNF bioassays and 
immunoassays (37). W ith the assays used in this study, 
such interference could be excluded; however, the 
question is whether circulating T N F a  retains its bio­
logical activity. Recently, van Zee et al (38) showed 
that a great excess of sTNFR is required to block the 
bioactivity of high concentrations of TN Fa, whereas 
lower T N F a  concentrations (approximately 4 times 
higher than those in our study) can be efficiently 
inhibited by an 8-9-fold excess of p55. The ratio of 
sTNFR to T N F a  in this study, together with the 
unchanged T N Fa  concentrations even in patients with 
clinical improvement, suggest that circulating T N Fa 
may not be biologically active.
The different course of the p55 versus the p75 
sTNFR and T N Fa  in the patients with clinical re­
sponse is interesting. The expression and shedding of 
both sTNFR may be distinctly regulated (27,39,40), 
but the main source of the circulating forms is still 
unknown. Interestingly, in a recent study, pretreat­
ment with ibuprofen in human experimental endotox- 
inemia increased and prolonged concentrations of 
T N Fa  and p75 sTNFR in the circulation without 
affecting p55 levels (41). It is therefore possible that 
concomitant N S A ID  therapy is also responsible for 
our findings.
Perhaps the most interesting observation in this 
study is that M T X  and A ZA  differ not only with 
respect to clinical efficacy, but also in their capacity to 
induce changes in circulating cytokine and soluble 
receptor concentrations. Corroborating the clinical 
results, the decreases in concentrations of sIL-2R and 
p55 were significant in the patients treated with M TX
(but not with AZA ), and M T X  was slightly more 
effective in decreasing immunoactive IL-6 levels. In 
view of the better clinical response obtained with 
M TX, it is possible that these differences are due to a 
more effective suppression of the inflammation by this 
drug, rather than to a specific effect of M TX. The early 
and pronounced decrease in IL-6 bioactivity in pa­
tients treated with A Z A  has to be explained by the 
inhibitory effects of circulating A Z A  or its metabolites 
in the bioassay (Barrera P et al: unpublished observa­
tions). This bioassay is therefore not suitable for 
evaluating IL-6 concentrations in patients treated with 
this drug.
Decreases in sIL-2R concentrations in R A  have 
been observed during treatment with amiprilose HC1 
(Therafectin; Greenwich Pharmaceuticals, Fort Wash­
ington, PA) (28) and with corticosteroids (30), but not 
with intramuscular gold (42). Decreases in IL-6 con­
centrations have been reported with intramuscular (43) 
and oral gold (44), while for sulfasalazine the results 
are contradictory (44,45). Neither M T X  nor A Z A  
altered T N Fa  concentrations in this study, but de­
creases have been observed during therapy with cor­
ticosteroids (36) and sulfasalazine (45).
Taken together, these results indicate that di­
verse D M A R D s distinctly affect circulating cytokines 
and soluble receptors. The differences in cytokine 
patterns between patients with improvement versus 
those without, suggest that measurements of sIL-2R, 
p55, and IL-6 may be useful in the evaluation of 
therapeutic response. Further studies are needed to 
determine whether these effects are causally related to 
disease-modifying activity or merely reflect epiphe- 
nomena.
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